Changzhou Fangyuan Pharma is ready for clinical trials in China to test its nearly decade-long work on a tricky-to-make semisynthetic, methicillin-resistant…

Hanmi Pharmaceutical eyes branded drugs, fast-paced R&D and investment in China to get growth on track.

Military hospitals in China are reportedly offering unapproved immunotherapy and stem cell treatments, promising miracle cures at steep fees.

Two examples of efforts to expand data insights into cancer in China show the potential scope of a national "big data plan" for healthcare for both…

Astellas Pharma and Shionogi are looking to sell branded drugs that have expired patents in Japan in a play to take the funds and invest in newer therapies or…

BeiGene has dosed the first patient in a Phase I clinical trial for a combination of candidates, BGB-3111 and BGB-A317, aimed at B-cell malignancies.

South Korean biopharma Celltrion says it is on the path to come up with the first antibody therapy to treat the flu as the candidate, CT-P27, moves through…

Explosive growth for China's biopharma industry spurred by the return of talent after high-profile stints at companies and universities in the U.S. will…

Osaka-based Takeda Pharmaceutical has returned Japan rights for Amgen candidates fulranumab and trebananib as it continues its fast-paced reshuffle of its…